We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

YB:NASDAQYuanbao Inc. Analysis

Data as of 2026-05-12 - not real-time

$15.81

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Yuanbao Inc. trades at $15.81, well below its 20‑day ($16.73), 50‑day ($17.95) and 200‑day ($21.04) moving averages, signaling a bearish technical backdrop. The RSI of 39.9 and a bearish MACD histogram reinforce short‑term downside pressure, while the price sits just above a solid support at $15.06 with resistance near $18.80. Despite the technical weakness, the fundamentals are exceptionally strong: revenue grew 32% YoY, gross margins sit at 96%, operating margins at 34%, and ROE exceeds 50%. Valuation metrics are strikingly cheap, with a trailing PE of 3.9 versus an industry average of 39, a price‑to‑sales of 0.17 and a forward PE of 3.2, suggesting a potential upside of roughly 40% to the consensus target of $22.07. The company holds $3.96 bn in cash against minimal debt, and its beta of 1.16 and 30‑day volatility of nearly 50% indicate heightened market sensitivity. The Fear & Greed Index reading of “Extreme Greed” reflects strong market appetite, yet the low trading volume and modest market cap raise liquidity concerns. Overall, YB presents a classic value‑growth dichotomy: compelling fundamentals and valuation upside countered by bearish technicals and elevated risk factors.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price below key moving averages indicating bearish momentum
  • Proximity to support level at $15.06
  • High short‑term volatility and low trading volume

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Robust revenue growth of 32% and high profitability margins
  • Significant valuation discount (PE 3.9 vs industry 39)
  • Strong cash position relative to minimal debt

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Sustained high ROE and ROA indicating efficient capital use
  • Potential upside to analyst target price of $22.07 (+~40%)
  • Long‑run market share expansion in China’s insurance brokerage sector

Key Metrics & Analysis

Financial Health

Revenue Growth32.20%
Profit Margin29.90%
P/E Ratio3.9
ROE50.94%
ROA22.47%
Debt/Equity0.24
P/B Ratio1.5
Industry P/E39.0

Technical Analysis

TrendBearish
RSI39.9
Support$15.06
Resistance$18.80
MA 20$16.73
MA 50$17.95
MA 200$21.04
MACDBearish
VolumeStable
Fear & Greed Index88.61

Valuation

Target Price$22.07
Upside/Downside39.57%
GradeUndervalued
TypeBlend

Risk Assessment

Beta1.16
Volatility49.81%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.